Dr. Eyre on BTK Inhibitors in Combination With Venetoclax for MCL

Dr. Eyre Discusses Venetoclax Monotherapy in MCLПодробнее

Dr. Eyre on Results of Venetoclax in Relapsed/Refractory MCLПодробнее

Dr. Rule on the Combination of Venetoclax and Ibrutinib in MCLПодробнее

Dr. Rule on the Role of BTK Inhibitors in MCLПодробнее

Toby Eyre | Would venetoclax monotherapy be a good option for R/R MCL post-BTK inhibitor therapy?Подробнее

BTK inhibitors for R/R MCL: current uses and insights from the ViPOR studyПодробнее

Dr. Eyre on Resistance to BTK Inhibition in MCLПодробнее

Venetoclax: an unmet need in R/R mantle cell lymphoma after BTK inhibitorsПодробнее

Rebooting the BTK Inhibitor Sequence in MCLПодробнее

Dr. Kaplan on the Combination of Ibrutinib and Venetoclax in MCLПодробнее

Dr. Ruan Discusses BTK Inhibitors in MCLПодробнее

Dr. Goy Discusses Ibrutinib With Venetoclax in MCLПодробнее

Novel therapies for patients with MCL after failed response to BTK inhibitorsПодробнее

Dr. Ritchie on the Immunologic Impact of Long-Term Venetoclax/Ibrutinib in R/R MCLПодробнее

Durable responses to ibrutinib and venetoclax in R/R MCL: 3-year AIM updateПодробнее

SYMPATICO: safety and efficacy of ibrutinib plus venetoclax for R/R MCLПодробнее

Dr. Patel on Differences Between BTK Inhibitors in MCLПодробнее

Advancements in MCL treatmentПодробнее

Selecting BTK inhibitors for patients with MCLПодробнее